Published in Cancer on September 01, 1975
Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia (2008) 8.85
Multiple myeloma. Blood (2008) 5.88
Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science (2011) 4.46
Treatment of multiple myeloma. Nat Rev Clin Oncol (2011) 2.46
IMWG consensus on risk stratification in multiple myeloma. Leukemia (2013) 2.28
Primary bioassay of human myeloma stem cells. J Clin Invest (1977) 2.25
In anemia of multiple myeloma, hepcidin is induced by increased bone morphogenetic protein 2. Blood (2010) 2.03
MR imaging of therapy-induced changes of bone marrow. Eur Radiol (2006) 1.95
Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma. Biol Blood Marrow Transplant (2013) 1.88
Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system. Leukemia (2008) 1.77
Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma. Haematologica (2010) 1.73
Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. J Clin Invest (1989) 1.72
A review for solitary plasmacytoma of bone and extramedullary plasmacytoma. ScientificWorldJournal (2012) 1.67
Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. Blood (2005) 1.66
Proteomic contributions to personalized cancer care. Mol Cell Proteomics (2008) 1.46
Religious struggle and religious comfort in response to illness: health outcomes among stem cell transplant patients. J Behav Med (2005) 1.45
Positron Emission Tomography (PET) in Oncology. Cancers (Basel) (2014) 1.41
Cancer phenotype as the outcome of an evolutionary game between normal and malignant cells. Br J Cancer (2009) 1.35
Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol (2012) 1.35
Serum concentration of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myeloma. Br J Cancer (1992) 1.34
Extramedullary plasmacytomas in the head and neck region. Eur Arch Otorhinolaryngol (2008) 1.33
Interleukin 3 and interleukin 6 synergistically promote the proliferation and differentiation of malignant plasma cell precursors in multiple myeloma. J Exp Med (1989) 1.32
Identification of malignant plasma cell precursors in the bone marrow of multiple myeloma. J Clin Invest (1985) 1.30
Analysis of signal transducer and activator of transcription 3 (Stat 3) pathway in multiple myeloma: Stat 3 activation and cyclin D1 dysregulation are mutually exclusive events. Am J Pathol (2003) 1.29
Image-guided total-marrow irradiation using helical tomotherapy in patients with multiple myeloma and acute leukemia undergoing hematopoietic cell transplantation. Int J Radiat Oncol Biol Phys (2008) 1.25
Routine bone marrow examination in the management of acute lymphoblastic leukaemia of childhood. J Clin Pathol (1981) 1.21
Chemokine receptor CCR2 is expressed by human multiple myeloma cells and mediates migration to bone marrow stromal cell-produced monocyte chemotactic proteins MCP-1, -2 and -3. Br J Cancer (2003) 1.18
A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients. Br J Cancer (1988) 1.17
Should patients with renal failure associated with myeloma be dialysed? Br Med J (Clin Res Ed) (1983) 1.17
Whole-body MRI in the detection of bone marrow infiltration in patients with plasma cell neoplasms in comparison to the radiological skeletal survey. Eur Radiol (2006) 1.16
Diagnosis and treatment of bone disease in multiple myeloma: spotlight on spinal involvement. Scientifica (Cairo) (2013) 1.15
The prognostic value of serum beta 2 microglobulin compared with other presentation features in myelomatosis. Br J Cancer (1985) 1.15
Comparison of whole-body 64-slice multidetector computed tomography and conventional radiography in staging of multiple myeloma. Eur Radiol (2007) 1.12
Ras oncogene mutation in multiple myeloma. J Exp Med (1989) 1.11
International Myeloma Working Group recommendations for global myeloma care. Leukemia (2013) 1.10
11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma. World J Surg Oncol (2007) 1.09
Smoldering multiple myeloma requiring treatment: time for a new definition? Blood (2013) 1.09
Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data. Haematologica (2012) 1.09
Infused vincristine and adriamycin with high dose methylprednisolone (VAMP) in advanced previously treated multiple myeloma patients. Br J Cancer (1988) 1.09
Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study. Cooperative Group of Study and Treatment of Multiple Myeloma. Br J Cancer (2000) 1.09
Serum beta 2-microglobulin in myelomatosis: potential value in stratification and monitoring. Br J Cancer (1980) 1.08
Multiple Myeloma: Diagnosis and Treatment. Mayo Clin Proc (2016) 1.07
Role of radiography, MRI and FDG-PET/CT in diagnosing, staging and therapeutical evaluation of patients with multiple myeloma. Ann Hematol (2009) 1.07
Anaemia in patients with myelomatosis. Br J Cancer (1982) 1.07
Whole-body imaging of the musculoskeletal system: the value of MR imaging. Skeletal Radiol (2007) 1.06
Evaluation of serum beta 2-microglobulin as a prognostic indicator in myelomatosis. Br J Cancer (1983) 1.05
Immunological factors and risk of infection in plateau phase myeloma. J Clin Pathol (1995) 1.05
VAD chemotherapy as remission induction for multiple myeloma. Br J Cancer (1995) 1.04
Multiple myeloma. Curr Probl Cancer (2009) 1.04
Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials. Haematologica (2012) 1.03
Comorbidity as a prognostic variable in multiple myeloma: comparative evaluation of common comorbidity scores and use of a novel MM-comorbidity score. Blood Cancer J (2011) 1.03
Role of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results. Eur J Nucl Med Mol Imaging (2006) 1.02
Expression of genes encoding for proteins involved in heparan sulphate and chondroitin sulphate chain synthesis and modification in normal and malignant plasma cells. Br J Haematol (2009) 1.00
Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3. Blood (2013) 1.00
Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg/m2 of melphalan in multiple myeloma: results of a pilot study including biological aspects. Bone Marrow Transplant (2005) 1.00
Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop. J Clin Invest (1996) 1.00
Immunoglobulin and free light chain abnormalities in Gaucher disease type I: data from an adult cohort of 63 patients and review of the literature. Ann Hematol (2008) 1.00
Polymorphisms of nuclear factor-κB family genes are associated with development of multiple myeloma and treatment outcome in patients receiving bortezomib-based regimens. Haematologica (2011) 0.99
High-frequency promoter hypermethylation of the deleted in liver cancer-1 gene in multiple myeloma. J Clin Pathol (2006) 0.99
Is the International Staging System superior to the Durie-Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant. Leukemia (2009) 0.98
Expression of the neural cell adhesion molecule (CD56) by human myeloma cells. Clin Exp Immunol (1991) 0.98
Multiple myeloma. BMJ (1994) 0.98
The role of positron emission tomography-computed tomography and magnetic resonance imaging in diagnosis and follow up of multiple myeloma. Haematologica (2014) 0.98
Clinical value of ¹¹C-methionine PET/CT in patients with plasma cell malignancy: comparison with ¹⁸F-FDG PET/CT. Eur J Nucl Med Mol Imaging (2013) 0.98
Guidelines on the diagnosis and management of multiple myeloma treatment: Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular Project guidelines: Associação Médica Brasileira - 2012. Rev Bras Hematol Hemoter (2013) 0.98
Current and future imaging modalities for multiple myeloma and its precursor states. Leuk Lymphoma (2011) 0.97
Prognostic factor analyses of myeloma survival with intergroup trial S9321 (INT 0141): examining whether different variables govern different time segments of survival. Ann Hematol (2010) 0.96
Characteristics of older newly diagnosed cancer patients refusing cancer treatments. Support Care Cancer (2010) 0.96
Efficacy of bortezomib as first-line treatment for patients with multiple myeloma. Clin Med Insights Oncol (2013) 0.95
Membrane phenotype and functional behaviour of T lymphocytes in multiple myeloma: correlation with clinical stages of the disease. Clin Exp Immunol (1984) 0.95
Normal and clonal B lineage cells can be distinguished by their differential expression of B cell antigens and adhesion molecules in peripheral blood from multiple myeloma (MM) patients--diagnostic and clinical implications. Clin Exp Immunol (1998) 0.95
New insights into the treatment of multiple myeloma with histone deacetylase inhibitors. Curr Pharm Des (2013) 0.95
Comparison of imaging with FDG PET/CT with other imaging modalities in myeloma. Skeletal Radiol (2006) 0.95
Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol (2016) 0.94
Multiple myeloma. Cancer Imaging (2004) 0.94
Myeloma today: Disease definitions and treatment advances. Am J Hematol (2016) 0.94
Safety and tolerability of the antimicrobial peptide human lactoferrin 1-11 (hLF1-11). BMC Med (2009) 0.94
Prevalence of bisphosphonate associated osteonecrosis of the jaws in multiple myeloma patients. Head Face Med (2010) 0.94
A gene expression-based predictor for myeloma patients at high risk of developing bone disease on bisphosphonate treatment. Clin Cancer Res (2011) 0.93
The value of FDG PET/CT in the initial staging and bone marrow involvement of patients with multiple myeloma. Skeletal Radiol (2011) 0.93
Cytokines involved in the progression of multiple myeloma. Clin Exp Immunol (1993) 0.92
Laminin-1-induced migration of multiple myeloma cells involves the high-affinity 67 kD laminin receptor. Br J Cancer (2001) 0.92
Plasma cell leukemia: case series from a tertiary center with review of literature. Indian J Hematol Blood Transfus (2011) 0.91
Ratio of involved/uninvolved immunoglobulin quantification by Hevylite™ assay: clinical and prognostic impact in multiple myeloma. Exp Hematol Oncol (2012) 0.91
Incidence of chromosome numerical changes in multiple myeloma: fluorescence in situ hybridization analysis using 15 chromosome-specific probes. Am J Pathol (1996) 0.91
(11)C-acetate as a new biomarker for PET/CT in patients with multiple myeloma: initial staging and postinduction response assessment. Eur J Nucl Med Mol Imaging (2013) 0.90
Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma. J Cancer Res Clin Oncol (2012) 0.90
Importance of quantitative histology of bone changes in monoclonal gammopathy. Br J Cancer (1986) 0.90
Telomerase activity in plasma cell dyscrasias. Br J Cancer (2001) 0.90
Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells. Arch Immunol Ther Exp (Warsz) (2008) 0.90
Problems monitoring response in multiple myeloma. Cancer Imaging (2005) 0.90
Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation. Oncotarget (2015) 0.90
Expression of myeloid antigen in neoplastic plasma cells is related to adverse prognosis in patients with multiple myeloma. Biomed Res Int (2014) 0.90
Influence of body mass index on survival in veterans with multiple myeloma. Oncologist (2013) 0.90
Pathological crystallization of human immunoglobulins. Proc Natl Acad Sci U S A (2012) 0.90
A prognostic index for multiple myeloma. Br J Cancer (1996) 0.90
MicroRNA: important player in the pathobiology of multiple myeloma. Biomed Res Int (2014) 0.89
Immunohistochemical analysis of cyclin D1 shows deregulated expression in multiple myeloma with the t(11;14). Am J Pathol (2000) 0.89
Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med (2001) 11.73
Primary bioassay of human tumor stem cells. Science (1977) 9.69
A new type of synthetic peptide library for identifying ligand-binding activity. Nature (1991) 7.81
Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs. N Engl J Med (1978) 5.78
High speed scintillation autoradiography. Science (1975) 5.15
Raised serum levels of tumour necrosis factor in parasitic infections. Lancet (1986) 3.23
Evidence for the secretion of an osteoclast stimulating factor in myeloma. N Engl J Med (1974) 2.97
Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol (1989) 2.89
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia (2007) 2.76
Primary bioassay of human myeloma stem cells. J Clin Invest (1977) 2.25
Prognostic value of pretreatment serum beta 2 microglobulin in myeloma: a Southwest Oncology Group Study. Blood (1990) 2.24
Direct cloning of human ovarian carcinoma cells in agar. Cancer Res (1978) 2.24
Immunoglobulin synthesis and total body tumor cell number in IgG multiple myeloma. J Clin Invest (1970) 2.21
B-cell neoplasia in man. Lancet (1974) 2.11
Prevention of doxorubicin-induced hair loss with scalp hypothermia. N Engl J Med (1979) 1.94
Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukaemia Group of the EORTC and the HOVON. Lancet (1992) 1.92
Production of lymphotoxin, a bone-resorbing cytokine, by cultured human myeloma cells. N Engl J Med (1987) 1.82
Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein. Cancer Res (1986) 1.75
"Sandwich" solid phase radioimmunoassay for the quantitative deterimination of human immunoglobulins. J Immunol (1969) 1.74
Relation of cytogenetic abnormalities and clinical outcome in metastatic melanoma. N Engl J Med (1990) 1.72
P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol (1991) 1.64
Evaluation of race as a prognostic factor in multiple myeloma. An ancillary of Southwest Oncology Group Study 8229. J Clin Oncol (1996) 1.57
Effect of host-cell interactions on clonogenic carcinoma cells in human malignant effusions. Br J Cancer (1980) 1.52
Polyamines as markers of response and disease activity in cancer chemotherapy. Cancer Res (1977) 1.52
Dose response evaluation of adriamycin in human neoplasia. Cancer (1977) 1.51
Preparation of permanent slides of intact soft-agar colony cultures of hematopoietic and tumor stem cells. Cancer Res (1979) 1.51
Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1; Leu-19). Blood (1990) 1.50
Myeloperoxidase deficiency. Immunologic study of a genetic leukocyte defect. N Engl J Med (1970) 1.41
Prognostic correlation of plasma cell acid phosphatase and beta-glucuronidase in multiple myeloma: a Southwest Oncology Group study. Blood (1991) 1.40
Immunology of the lower respiratory tract. II. The plaque-forming response of canine lymphoid tissues to sheep erythrocytes after intrapulmonary or intravenous immunization. J Clin Invest (1974) 1.39
Combination chemotherapy with adriamycin and cyclophosphamide for advanced breast cancer. Cancer (1975) 1.39
Kinetics of tumor growth and regression in IgG multiple myeloma. J Clin Invest (1972) 1.38
Comparison of bone scintigraphy and radiography in multiple myeloma. Radiology (1980) 1.37
Human tumor colony assay and chemosensitivity testing. Cancer Treat Rep (1984) 1.30
Immunoglobulin synthesis and tumour cell number and the natural history of multiple myeloma. Br Med J (1971) 1.30
Serum beta2 microglobulin and survival duration in multiple myeloma: a simple reliable marker for staging. Br J Haematol (1983) 1.28
Amyloid production in human myeloma stem-cell culture, with morphologic evidence of amyloid secretion by associated macrophages. N Engl J Med (1982) 1.27
Application of a human tumor colony-forming assay to new drug screening. Cancer Res (1985) 1.26
Skin reactivity in patients with cancer. Impaired delayed hypersensitivity or faulty inflammatory response? N Engl J Med (1971) 1.24
Antiproliferative and antitumor activity of the 2-cyanoaziridine compound imexon on tumor cell lines and fresh tumor cells in vitro. J Natl Cancer Inst (1992) 1.23
Staging and kinetics of multiple myeloma. Semin Oncol (1986) 1.19
Pretreatment tumor mass, cell kinetics, and prognosis in multiple myeloma. Blood (1980) 1.18
Immunoglobulin synthesis and tumor kinetics of multiple myeloma. Semin Hematol (1973) 1.17
P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood (1993) 1.16
Immunology of the lower respiratory tract. Functional properties of bronchoalveolar lymphocytes obtained from the normal canine lung. J Clin Invest (1973) 1.15
Polyamines as predictors of success and failure in cancer chemotherapy. Lancet (1975) 1.14
Inhibition of human melanoma colony formation by retinoids. Cancer Res (1979) 1.13
Lymphocyte stimulation: selective destruction of cells during blastogenic response to transplantation antigens. Science (1971) 1.13
Hydrolysis and protein binding of melphalan. J Pharm Sci (1978) 1.10
Peptide-encoding for structure determination of nonsequenceable polymers within libraries synthesized and tested on solid-phase supports. Pept Res (1993) 1.07
Prognostic factors and staging in multiple myeloma: a reappraisal. J Clin Oncol (1986) 1.07
Cytogenetics of 158 patients with regional or disseminated melanoma. Subset analysis of near-diploid and simple karyotypes. Cancer Genet Cytogenet (1995) 1.05
Indium-111 bleomycin tumor scanning in lymphoma. Med Pediatr Oncol (1975) 1.04
Relation of osteoclast activating factor production to extent of bone disease in multiple myeloma. Br J Haematol (1981) 1.04
Reappraisal of plateau phase in myeloma. Lancet (1980) 1.04
Alternating combination chemotherapy and levamisole improves survival in multiple myeloma: a Southwest Oncology Group Study. J Clin Oncol (1983) 1.04
The current status and future prospects of treatment for multiple myeloma. Clin Haematol (1982) 1.03
Phase I pharmacokinetic trial and correlative in vitro phase II tumor kinetic study of Apomine (SR-45023A), a novel oral biphosphonate anticancer drug. Clin Cancer Res (2001) 1.03
Systemic toxic effects associated with high-dose verapamil infusion and chemotherapy administration. J Natl Cancer Inst (1991) 1.03
Model for estimation of clinically achievable plasma concentrations for investigational anticancer drugs in man. Cancer Treat Rep (1986) 1.03
Development of an agar-methyl cellulose clonogenic assay for cells in transitional cell carcinoma of the human bladder. Cancer Res (1979) 1.02
Use of an image analysis system to count colonies in stem cell assays of human tumors. Prog Clin Biol Res (1980) 1.02
In vitro clonal assay for human metastatic melanoma cells. Stem Cells (1981) 1.01
Effects of interleukin-4 on the in vitro growth of human lymphoid and plasma cell neoplasms. Blood (1990) 1.01
Adjuvant treatment of node-positive breast cancer with adriamycin-cyclophosphamide with or without radiation therapy: interim results of an ongoing clinical trial. Recent Results Cancer Res (1982) 0.99
High-pressure liquid chromatographic analysis of melphalan in plasma. J Pharm Sci (1978) 0.99
CALLA-positive myeloma: an aggressive subtype with poor survival. Blood (1985) 0.99
Application of in vitro soft agar techniques for growth of tumor cells to the study of colon cancer. Cancer (1980) 0.99
Delineation of a novel pre-B cell component in plasma cell myeloma: immunochemical, immunophenotypic, genotypic, cytologic, cell culture, and kinetic features. Blood (1987) 0.99
cDNA microarray analysis of multidrug resistance: doxorubicin selection produces multiple defects in apoptosis signaling pathways. J Pharmacol Exp Ther (2001) 0.99
High-dose melphalan with autotransplantation for refractory multiple myeloma: results of a Southwest Oncology Group phase II trial. J Clin Oncol (1999) 0.98
Pharmacologic studies of anticancer drugs with the human tumor stem cell assay. Cancer Chemother Pharmacol (1981) 0.98
Bleomycin pharmacokinetics in man. I. Intravenous administration. Cancer Chemother Pharmacol (1978) 0.96
In vitro drug assay: pharmacologic considerations. Prog Clin Biol Res (1980) 0.96
Interactions of human leukocyte interferon with vinca alkaloids and other chemotherapeutic agents against human tumors in clonogenic assay. Cancer Chemother Pharmacol (1983) 0.96
Quantitation of drug sensitivity by human metastatic melanoma colony-forming units. Br J Cancer (1981) 0.96
Multiple release of equimolar amounts of peptides from a polymeric carrier using orthogonal linkage-cleavage chemistry. Int J Pept Protein Res (1993) 0.95
Phase II study of fludarabine phosphate in multiple myeloma. A Southwest Oncology Group study. Invest New Drugs (1990) 0.95
Sandwich solid phase radioimmunoassays for the characterization of human immunoglobulins synthesized in vitro. J Immunol (1970) 0.95
New drugs in ovarian cancer and malignant melanoma: in vitro phase II screening with the human tumor stem cell assay. Cancer Treat Rep (1981) 0.94
Is myeloma really a monoclonal disease? Br J Haematol (1984) 0.93
Interaction of allopurinol with 6-mercaptopurine and azathioprine. Biomed Pharmacother (1982) 0.93
Myelomonocytic antigen positive multiple myeloma. Blood (1989) 0.93
Effect of epidermal growth factor on clonogenic growth of primary human tumor cells. Int J Cancer (1982) 0.93
Estrogen and progesterone receptors in some human myeloma cell lines and murine hybridomas. J Steroid Biochem (1988) 0.93
Role of gamma globulin for immunoprophylaxis in multiple myeloma. N Engl J Med (1967) 0.93